The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance become a problem?
New HIV drugs should be classed as inferior if they carry a higher risk of resistance
Dolutegravir resistance is rare, but some risk factors can up the odds
Intermittent dosing on HIV dual therapy leads to higher rate of treatment failure
Resistance history does not affect response to dolutegravir / lamivudine
Top 5 stories on sexual health from CROI 2023
Rilpivirine resistance may be barrier to long-acting injectable treatment in South Africa
Failure of integrase inhibitor-based regimens may be due to a completely novel form of resistance
Doxycycline PEP after sex appears ineffective for cisgender women
